{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:55:45Z","timestamp":1790060145881,"version":"4.0.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T00:00:00Z","timestamp":1498435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy and safety of palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, combined with fulvestrant and goserelin was assessed in premenopausal women with advanced breast cancer (ABC) who had progressed on prior endocrine therapy (ET).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>One hundred eight premenopausal endocrine-refractory women \u226518 years with hormone receptor\u2013positive (HR+)\/human epidermal growth factor receptor 2\u2013negative (HER2\u2212) ABC were among 521 women randomized 2:1 (347:174) to fulvestrant (500 mg)\u2009\u00b1\u2009goserelin with either palbociclib (125 mg\/day orally, 3 weeks on, 1 week off) or placebo. This analysis assessed whether the overall tolerable safety profile and significant progression-free survival (PFS) improvement extended to premenopausal women. Potential drug-drug interactions (DDIs) and ovarian suppression with goserelin were assessed via plasma pharmacokinetics and biochemical analyses, respectively. (ClinicalTrials.gov identifier: NCT01942135)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median PFS for premenopausal women in the palbociclib (n\u2009=\u200972) versus placebo arm (n\u2009=\u200936) was 9.5 versus 5.6 months, respectively (hazard ratio, 0.50, 95% confidence interval: 0.29\u20130.87), and consistent with the significant PFS improvement in the same arms for postmenopausal women. Any-grade and grade \u22643 neutropenia, leukopenia, and infections were among the most frequent adverse events reported in the palbociclib arm with concurrent goserelin administration. Hormone concentrations were similar between treatment arms and confirmed sustained ovarian suppression. Clinically relevant DDIs were not observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Palbociclib combined with fulvestrant and goserelin was an effective and well-tolerated treatment for premenopausal women with prior endocrine-resistant HR+\/HER2\u2212 ABC. Inclusion of both premenopausal and postmenopausal women in pivotal combination ET trials facilitates access to novel drugs for young women and should be considered as a new standard for clinical trial design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0072","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T20:45:20Z","timestamp":1498509920000},"page":"1028-1038","source":"Crossref","is-referenced-by-count":122,"title":["Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results"],"prefix":"10.1093","volume":"22","author":[{"given":"Sibylle","family":"Loibl","sequence":"first","affiliation":[{"name":"German Breast Group GBG Forschungs GmbH, Neu-Isenburg, Germany"},{"name":"Centre for Haematology and Oncology Bethanien, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Turner","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital and Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungsil","family":"Ro","sequence":"additional","affiliation":[{"name":"National Cancer Center, Goyang-si, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[{"name":"Aichi Cancer Center Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[{"name":"Breast Oncology, NHO Osaka National Hospital, Osaka-city, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[{"name":"Brustzentrum der Universit\u00e4t M\u00fcnchen (LMU), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Verma","sequence":"additional","affiliation":[{"name":"University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Folkerd","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital and Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Puyana Theall","sequence":"additional","affiliation":[{"name":"Pfizer Oncology, Cambridge, Massachussets, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Pfizer Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Huang","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Dowsett","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital and Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,26]]},"reference":[{"key":"2021122508222993300_onco12173-bib-0001","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.2010.29.7689","article-title":"Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial","volume":"29","author":"Ganz","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122508222993300_onco12173-bib-0002","author":"Howlander","year":"2016"},{"key":"2021122508222993300_onco12173-bib-0003","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jamcollsurg.2008.12.001","article-title":"Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease","volume":"208","author":"Gnerlich","year":"2009","journal-title":"J Am Coll Surg"},{"key":"2021122508222993300_onco12173-bib-0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-dependent relationship between young age at diagnosis and breast cancer survival","volume":"34","author":"Partridge","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122508222993300_onco12173-bib-0005","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdq220","article-title":"Survival differences among women with de novo stage IV and relapsed breast cancer","volume":"21","author":"Dawood","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122508222993300_onco12173-bib-0006","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122508222993300_onco12173-bib-0007","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1097\/MD.0000000000001006","article-title":"Phase II trial of goserelin and exemestane combination therapy in premenopausal women with locally advanced or metastatic breast cancer","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2021122508222993300_onco12173-bib-0008","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","article-title":"Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor\u2013positive, metastatic carcinoma of the breast in premenopausal women","volume":"28","author":"Carlson","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122508222993300_onco12173-bib-0009","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2009.26.5884","article-title":"Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy","volume":"28","author":"Park","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122508222993300_onco12173-bib-0010","doi-asserted-by":"crossref","first-page":"R337","DOI":"10.1530\/ERC-16-0121","article-title":"Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies","volume":"23","author":"Murphy","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"suppl 7","key":"2021122508222993300_onco12173-bib-0011","doi-asserted-by":"crossref","first-page":"vii11","DOI":"10.1093\/annonc\/mds232","article-title":"Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Cardoso","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122508222993300_onco12173-bib-0012","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/cncr.20481","article-title":"Efficacy of radiotherapy for ovarian ablation: Results of a breast intergroup study","volume":"101","author":"Hughes","year":"2004","journal-title":"Cancer"},{"key":"2021122508222993300_onco12173-bib-0013","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor\u2013positive metastatic breast cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122508222993300_onco12173-bib-0014","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/92.11.903","article-title":"Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study","volume":"92","author":"Klijn","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2021122508222993300_onco12173-bib-0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122508222993300_onco12173-bib-0016","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2011.03.031","article-title":"The turnover of estrogen receptor alpha by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy","volume":"82","author":"Wardell","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"2021122508222993300_onco12173-bib-0017","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.breast.2014.01.016","article-title":"The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer","volume":"23","author":"Ciruelos","year":"2014","journal-title":"Breast"},{"key":"2021122508222993300_onco12173-bib-0018","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2006.08.019","article-title":"Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer","volume":"43","author":"Robertson","year":"2007","journal-title":"Eur J Cancer"},{"key":"2021122508222993300_onco12173-bib-0019","article-title":"Comparison of the short-term biological effects of 7\u03b1-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17\u0392-diol(Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer","author":"Robertson","year":"2001","journal-title":"Cancer Res"},{"key":"2021122508222993300_onco12173-bib-0020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ejca.2007.11.007","article-title":"Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer","volume":"44","author":"Young","year":"2008","journal-title":"Eur J Cancer"},{"key":"2021122508222993300_onco12173-bib-0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): A randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122508222993300_onco12173-bib-0022","author":"Finn","year":"2016"},{"key":"2021122508222993300_onco12173-bib-0023","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor\u2013positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508222993300_onco12173-bib-0024","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2021122508222993300_onco12173-bib-0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"2021122508222993300_onco12173-bib-0026","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"2021122508222993300_onco12173-bib-0027","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508222993300_onco12173-bib-0028","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1007\/s00268-010-0683-1","article-title":"Is breast cancer the same disease in Asian and Western countries?","volume":"34","author":"Leong","year":"2010","journal-title":"World J Surg"},{"key":"2021122508222993300_onco12173-bib-0029","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.ejca.2012.03.002","article-title":"Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer","volume":"48","author":"Bartsch","year":"2012","journal-title":"Eur J Cancer"},{"key":"2021122508222993300_onco12173-bib-0030","year":"2015"},{"key":"2021122508222993300_onco12173-bib-0031","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3892\/or.2013.2312","article-title":"Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial","volume":"29","author":"Nishimura","year":"2013","journal-title":"Oncol Rep"},{"key":"2021122508222993300_onco12173-bib-0032","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/oxfordjournals.annonc.a058837","article-title":"Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study","volume":"5","author":"Boccardo","year":"1994","journal-title":"Ann Oncol"},{"key":"2021122508222993300_onco12173-bib-0033","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","article-title":"Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials","volume":"19","author":"Klijn","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122508222993300_onco12173-bib-0034","year":"2016"},{"key":"2021122508222993300_onco12173-bib-0035","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.2015.62.3728","article-title":"Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer","volume":"34","author":"Dowsett","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122508222993300_onco12173-bib-0036","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-14-0697","article-title":"Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer","volume":"5","author":"Kruchten","year":"2015","journal-title":"Cancer Discov"},{"key":"2021122508222993300_onco12173-bib-0037","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1158\/1055-9965.EPI-10-0081","article-title":"Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and men in epidemiologic studies","volume":"19","author":"Stanczyk","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122508222993300_onco12173-bib-0038","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1530\/EJE-15-0831","article-title":"Steroid sulfatase activity in subcutaneous and visceral adipose tissue: A comparison between pre- and postmenopausal women","volume":"174","author":"Paatela","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2021122508222993300_onco12173-bib-0039","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ejca.2014.01.007","article-title":"Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors","volume":"50","author":"L\u00f8nning","year":"2014","journal-title":"Eur J Cancer"},{"key":"2021122508222993300_onco12173-bib-0040","year":"2017"},{"key":"2021122508222993300_onco12173-bib-0041","year":"2017"},{"issue":"suppl","key":"2021122508222993300_onco12173-bib-0042","doi-asserted-by":"crossref","first-page":"iv154","DOI":"10.1093\/annonc\/mdu331.22","article-title":"A population pharmacokinetic (PK) analysis of palbociclib (PD-0332991) in patients (pts) with advanced solid tumors [abstract 462P]","volume":"25","author":"Sun","year":"2014","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0072","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0072","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/9\/1028\/41916211\/oncolo_22_9_1028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/9\/1028\/41916211\/oncolo_22_9_1028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T03:23:35Z","timestamp":1640402615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/9\/1028\/6444567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,26]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,6,26]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0072","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9,1]]},"published":{"date-parts":[[2017,6,26]]}}}